Clinical trials: Macular Neovascularisation
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Epiretinal Membrane, Age Related Macular Degeneration
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
- Trial name
- NCT01846351
- Volunteers
- 16 people
- Sponsor
- New England Retina Associates
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01940900
- Testing
- E10030, ranibizumab
- Where
- 121 sites in United States, Argentina and 9 more
- Volunteers
- 627 people
- Sponsor
- Ophthotech Corporation
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Telangiectasia
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
This study will examine whether the drug ranibizumab is an effective treatment for macular telangiectasia, a condition in which existing blood vessels near the macula (the back part of the eye responsible for sharp central…
- Trial name
- NCT00457067
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration Choroidal Neovascularization
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability…
- Trial name
- Fixed farcimab (NCT06742307)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Hospital Authority, Hong Kong
Retinal Disease, Retinal Detachment
High Resolution Optical Coherence Tomography
Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases
- Conditions
- Retinal Disease, Retinal Detachment, Retinal Vein Occlusion, Retinal Dystrophy
- Trial name
- NCT05130385
- Testing
- High-resolution optical coherence tomography (High-Res-OCT), Standard spectral domain OCT (SD-OCT)
- Where
- Switzerland
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Macular Pigment Optical Density
Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration
- Trial name
- NCT03433885
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Diabetic Macular Edema, Macular Edema
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Retinal Neovascularization
- Trial name
- NCT06595355
- Testing
- bevacizumab with oral curcumin
- Where
- Iran
- Volunteers
- 52 people
- Sponsor
- Isfahan University of Medical Sciences
Age Related Macular Degeneration
Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00603850)
- Testing
- ForeseeHome
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Age-Related Macular Degeneration
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal…
- Trial name
- NCT00429962
- Testing
- intravitreal ranibizumab, intravitreal ranibizumab & photodynamic therapy
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland
Macular Degeneration
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- CABERNET (NCT00454389)
- Testing
- Epi-Rad90™ Ophthalmic System, ranibizumab
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 494 people
- Sponsor
- NeoVista
Diabetic Retinopathy, Macular Degeneration
Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)
Injections of medicine into the middle of the eye (intravitreal injections) are commonly used in a multitude of retinal diseases.
- Trial name
- ITVR (NCT00695682)
- Testing
- intravitreal injection of infliximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Retina Research Foundation
Choroidal Neovascularization
Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc
- Trial name
- NCT00370786
- Testing
- bevacizumab
- Where
- Iran
- Volunteers
- 31 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis
Wet Age-Related Macular Degeneration
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema.
- Trial name
- ADVANCE (NCT00138632)
- Testing
- PTK787
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Novartis